Skip to main content
63°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
26.18
+1.75 (+7.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arvinas Inc
< Previous
1
2
Next >
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From
Arvinas Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High
February 06, 2024
Via
Investor Brand Network
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 18, 2024
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Chief Financial Officer Transition
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
February 14, 2024
From
CARRICK THERAPEUTICS LIMITED
Via
GlobeNewswire
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Jared Freedberg as General Counsel
January 16, 2024
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Oversubscribed $350 Million Private Placement
November 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023
From
Arvinas Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.